Prot #2215-CL-1101: Phase 1/2 Study of ASP2215 (Gilteritinib) Combined with Atezolizumab in Patients with Relapsed or Treatment Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)

Project: Research project

Project Details

StatusActive
Effective start/end date4/23/194/23/22

Funding

  • Syneos Health, Inc. (Prot #2215-CL-1101)
  • Astellas Pharma Global Development, Inc. (Prot #2215-CL-1101)